OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Feasibility Study Investigating Circulating Tumor DNA for Treatment Decisions

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody therapy

Secondary, to analyze developments in mutational status as reflected by cfDNA in plasma during therapy and at time of progression

Inclusion criteria

• Histopathologically verified metastatic colorectal cancer
• Indication for systemic palliative treatment with standard Anti-EGFR monoclonal antibodies
• Fit for therapy with EGFR inhibition
• Consent to treatment and sampling
• Measureable disease according to RECIST v 1.1
• Age ≥ 18

Exclusion criteria

• PS > 2
• Significant other cancer disease within 5 years of inclusion
• Conditions precluding sampling during therapy and treatment breaks.